{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-024034","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.226131+00:00","generated_at":"2026-05-22T01:33:40.572497+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Sanuwave Q1 revenue $9.34M (+61% YoY); operating income $1.0M; Q2 guidance 40-50% growth","bullets":["Revenue $9.34M, up 61% from $5.79M in Q1 2024; gross margin 79.0% vs 72.6%; GAAP operating income $1.0M.","Adjusted EBITDA $2.3M vs -$59k in Q1 2024; net loss $5.7M driven by change in fair value of derivative liabilities.","UltraMist systems sold: 98 (128% increase from 43); consumables revenue +43% to $5.8M.","Q2 2025 revenue guidance $10.0-10.7M (40-50% YoY); full year 2025 guidance reaffirmed at $48-50M.","CEO highlights strong pipeline, comfortable inventory levels for larger customer engagements."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-024034","json":"https://secwatch.observer/filing/0001628280-25-024034.json","markdown":"https://secwatch.observer/filing/0001628280-25-024034.md","text":"https://secwatch.observer/filing/0001628280-25-024034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000162828025024034/0001628280-25-024034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000162828025024034/snwv-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:33:40.572497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}